Grand View sets a precedent by being the first hospital to combine CardioTec, a new coronary blood flow imaging agent, with Toshiba nuclear medicine equipment. By using CardioTec, Grand View is able to offer its patients the most advanced non-invasive technique for diagnosing and treating patients with coronary disease.
Because of Grand View’s experience with cardiac nuclear studies since 1979, and its sophisticated equipment, Bristol Meyers Squibb asked Grand View to serve as its initial site for testing of their new cardiac imaging agent. Over a period of six months, a method using CardioTec was developed that served as a model for 200 other hospitals nationwide.
CardioTec allows physicians to image the heart within minutes of its administration to the patient. Speed of use, coupled with production of high-quality images, offers physicians the opportunity to make quick therapeutic decisions about possible lifesaving therapy for patients suffering from, or at risk for, heart attack. With CardioTec, a complete stress-related study can be performed in less than one hour compared to other cardiac imaging agents which routinely take from four to 24 hours. In addition, even without the use of a treadmill or bicycle test, Cardio Tec and detect the presence of coronary disease.
By using new agents such as Cardio Tec, Grand View continues to be in the forefront of patient care and the rapidly changing technologies in medicine.